Escobar-Morreale Héctor F, Botella-Carretero José I, Escobar del Rey Francisco, Morreale de Escobar Gabriella
Department of Endocrinology, Hospital Ramón y Cajal, Madrid, Spain.
J Clin Endocrinol Metab. 2005 Aug;90(8):4946-54. doi: 10.1210/jc.2005-0184. Epub 2005 May 31.
Combined infusion of levothyroxine plus liothyronine, as opposed to levothyroxine alone, is the only way of restoring the concentrations of circulating TSH, T4, and T3 as well as those of both T4 and T3 in all tissues of thyroidectomized rats. Considering the substantial differences in thyroid hormone secretion, transport, and metabolism between rats and humans, whether or not combined levothyroxine plus liothyronine replacement therapy has advantages over treatment with levothyroxine alone in hypothyroid patients is still questioned.
We conducted a systematic review of all the published controlled studies comparing treatment with levothyroxine alone with combinations of levothyroxine plus liothyronine in hypothyroid patients, identified through the Entrez-PubMed search engine.
Nine controlled clinical trials were identified that compared treatment with levothyroxine alone and treatment with combinations of levothyroxine plus liothyronine and included a sufficient number of adult hypothyroid patients to yield meaningful results. In only one study did the combined therapy appear to have beneficial effects on the mood, quality of life, and psychometric performance of the patients over levothyroxine alone. These results have not been confirmed by later studies using either T3 substitution protocols or approaches with fixed combinations of levothyroxine plus liothyronine, including those based on the physiological proportion in which T3 and T4 are secreted by the human thyroid. However, in some of these studies the patients preferred levothyroxine plus liothyronine combinations, for reasons not explained by changes in the psychological and psychometric tests employed. Yet patients' preference should be balanced against the possibility of adverse events resulting from the addition of liothyronine to levothyroxine, even in the small doses used in these studies.
Until clear advantages of levothyroxine plus liothyronine are demonstrated, the administration of levothyroxine alone should remain the treatment of choice for replacement therapy of hypothyroidism.
与单独使用左甲状腺素相比,联合输注左甲状腺素和碘塞罗宁是恢复甲状腺切除大鼠所有组织中循环促甲状腺激素(TSH)、甲状腺素(T4)和三碘甲状腺原氨酸(T3)以及T4和T3浓度的唯一方法。考虑到大鼠和人类在甲状腺激素分泌、运输和代谢方面存在显著差异,左甲状腺素联合碘塞罗宁替代疗法在甲状腺功能减退患者中是否比单独使用左甲状腺素治疗更具优势仍存在疑问。
我们通过Entrez-PubMed搜索引擎对所有已发表的对照研究进行了系统评价,这些研究比较了甲状腺功能减退患者单独使用左甲状腺素治疗与左甲状腺素联合碘塞罗宁治疗的效果。
共确定了9项对照临床试验,这些试验比较了单独使用左甲状腺素治疗和左甲状腺素联合碘塞罗宁治疗,纳入了足够数量的成年甲状腺功能减退患者以得出有意义的结果。只有一项研究表明,联合治疗在改善患者情绪、生活质量和心理测量表现方面比单独使用左甲状腺素更具优势。后来使用T3替代方案或左甲状腺素联合碘塞罗宁固定组合的研究(包括基于人类甲状腺分泌T3和T4的生理比例的研究)并未证实这些结果。然而,在其中一些研究中,患者更喜欢左甲状腺素联合碘塞罗宁的组合,原因并非所采用的心理和心理测量测试变化所能解释。然而,即使在这些研究中使用的小剂量情况下,患者偏好也应与左甲状腺素中添加碘塞罗宁可能导致不良事件的可能性相权衡。
在左甲状腺素联合碘塞罗宁的明显优势得到证实之前,单独使用左甲状腺素应仍然是甲状腺功能减退替代治疗的首选方法。